International market access is not a one-time fee. It is a per-country stack: registration, authorised representative, translation, local clinical or post-market data, ongoing maintenance. For a single class IIa device, the realistic five-market cost sits between EUR 90,000 and EUR 180,000 in year one, with EUR 30,000 to EUR 60,000 recurring annually. This post shows where every euro goes.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • A realistic international market access budget has five layers: registration and fees, local representative, translation, local data obligations, and ongoing maintenance.
  • For a class IIa device, a five-market year one budget of EUR 90,000 to EUR 180,000 is typical. Recurring annual cost lands at roughly one third of year one.
  • The cheapest market is never as cheap as the quote. Hidden costs sit in notarisation, legalisation, maintenance fees, translation updates, and audit support.
  • Authorised representative fees range from EUR 3,000 to EUR 15,000 per year depending on market, scope and device class.
  • Subtract to Ship for international: enter fewer markets, enter them fully, and sequence the rest behind first revenue.

Why this matters

Founders build international business cases on optimistic numbers. A distributor says "registration in our country is 5,000 euros" and that number goes into the spreadsheet. Twelve months later the same company has spent three times that and is still not on the market, because registration was one line in a five-line cost stack they did not see coming.

The problem is not that the information is hidden. It is that the full cost only shows up when you go through the process end to end. This post gives you the five-layer framework and applies it to five concrete markets so you can build a budget that survives contact with reality.

What the regulations actually require

Each market sets its own rules. For the EU the baseline is MDR Article 11 (authorised representative, where the manufacturer is not established in the Union), Article 29 and Article 31 (device and manufacturer registration in Eudamed), plus national registration obligations in several Member States. Outside the EU every market has its own framework — FDA in the US, MHRA in the UK, Swissmedic in Switzerland, TGA in Australia, NMPA in China, and so on.

What the regulations do not tell you is what it costs. That is where the five-layer framework comes in.

Layer 1 — Registration and fees. The direct fees paid to the competent authority or notified body for device registration, renewal, technical file review, or certificate maintenance.

Layer 2 — Local representative. An authorised representative, responsible person, US agent, local license holder or equivalent, depending on the market. Most non-domestic manufacturers legally require one.

Layer 3 — Translation and labelling. Labels, IFU, promotional materials, DoC, implant cards, SSCP and patient information in the national language(s). See the companion post on translation requirements.

Layer 4 — Local data obligations. Market-specific clinical data, local post-market surveillance activities, language-specific complaint handling, national incident reporting portals, local cybersecurity assessments.

Layer 5 — Ongoing maintenance. Annual registration renewals, AR retainer fees, periodic re-translation after IFU changes, local QMS maintenance, audit support, vigilance reporting infrastructure.

A worked example across five markets

Take a class IIa connected medical device (software plus a hardware sensor). The manufacturer is EU-based in Austria, already CE marked under MDR, and wants to enter five additional markets in year one: Germany (additional national registration), Switzerland, the United Kingdom, the United States, and Australia.

These are order-of-magnitude figures based on typical ranges observed in real startup programs. Your actuals will vary. Use them to stress-test your own plan.

Market 1: Germany (already EU member, additional national obligations)

  • Registration: entry in the national device information system (DMIDS) — typically no direct fee, but preparation effort.
  • Representative: not required (manufacturer in EU).
  • Translation: German IFU, labels, DoC. EUR 6,000–10,000 for 25,000 source words.
  • Local data: none additional beyond MDR.
  • Maintenance: internal effort to keep DMIDS entries current.
  • Year one: EUR 8,000–14,000. Recurring: EUR 1,500–3,000.

Market 2: Switzerland

  • Registration: Swissmedic notification and CH-REP requirement for non-Swiss manufacturers.
  • Representative: Swiss authorised representative (CH-REP) required. Typical fee EUR 4,000–10,000 per year.
  • Translation: German, French, Italian — three languages. EUR 18,000–30,000.
  • Local data: Swiss importer obligations, specific labelling including CH-REP details.
  • Maintenance: CH-REP annual fee, label updates.
  • Year one: EUR 25,000–45,000. Recurring: EUR 6,000–13,000.

Market 3: United Kingdom

  • Registration: MHRA registration for all medical devices placed on the UK market. Registration fees apply per device grouping.
  • Representative: UK Responsible Person (UKRP) required for non-UK manufacturers. Typical fee EUR 3,500–9,000 per year.
  • Translation: English already available — near-zero incremental.
  • Local data: UKCA marking transition requirements, post-market obligations to MHRA.
  • Maintenance: annual renewal, UKRP retainer, MHRA reporting.
  • Year one: EUR 8,000–18,000. Recurring: EUR 4,500–11,000.

Market 4: United States (FDA)

  • Registration: FDA establishment registration and listing annual user fee. 510(k) submission fees if applicable (standard fee is significant and changes annually).
  • Representative: US agent required for non-US manufacturers. Typical retainer EUR 2,000–6,000 per year.
  • Translation: English — near-zero incremental.
  • Local data: 510(k) submission content, potentially clinical or usability data, FDA QSR/QMSR compliance evidence.
  • Maintenance: annual establishment registration user fee, MDR (US medical device reporting), potential inspection readiness.
  • Year one: EUR 40,000–100,000 (dominated by 510(k) preparation and submission). Recurring: EUR 10,000–25,000.

Market 5: Australia (TGA)

  • Registration: ARTG (Australian Register of Therapeutic Goods) inclusion. Application and annual charges apply.
  • Representative: Australian sponsor required for non-Australian manufacturers. Typical fee EUR 4,000–10,000 per year.
  • Translation: English — near-zero incremental.
  • Local data: TGA accepts EU conformity assessment evidence for many device classes, reducing duplication, but requires sponsor-held technical documentation.
  • Maintenance: annual ARTG fees, sponsor retainer.
  • Year one: EUR 12,000–25,000. Recurring: EUR 6,000–14,000.

Five-market totals

  • Year one total: EUR 93,000–202,000 (dominated by US 510(k)).
  • Recurring annual: EUR 28,000–66,000.
  • Remove the US and the year one total drops to EUR 53,000–102,000 — which is why many EU startups defer the US until after EU revenue.

The Subtract to Ship playbook

Step 1: Build the five-layer matrix for every market you are considering. One row per layer, one column per market. Fill it in with ranges, not single numbers. The range is the truth.

Step 2: Stop treating registration as the cost. Registration fees are the smallest layer in most markets. The local representative and translation layers are larger and recurring. Budget them on equal footing.

Step 3: Sequence markets by revenue-per-euro-invested. A market where you have a signed distribution partner and a confirmed first order is worth more than three markets where you "might expand." Enter the committed market fully. Defer the speculative ones.

Step 4: Negotiate multi-year AR/representative contracts. Local representatives often offer better rates on multi-year contracts. If you are serious about a market, lock the rate.

Step 5: Use translation memory from day one. The cost delta between first translation and maintenance translation is huge if you use a translation memory system. Without it, every update is a new project. This is the single biggest lever on recurring translation cost.

Step 6: Treat the US like a separate business line. Do not bury US cost inside your "international expansion" budget. The 510(k) process, QMSR compliance and US agent stack is a major program on its own. Make it a separate decision with its own business case.

Step 7: Reserve 20% contingency. Every multi-market program runs into surprise costs: a missed translation, an unexpected notarised document, a certificate renewal that requires updated evidence. Budget the contingency explicitly.

Step 8: Reassess yearly. Your market access budget is not a one-time plan. Fees change. Authorities update rules. The UK-EU picture continues to shift. Review the matrix every year and update it.

Reality Check

  1. Have you built a five-layer cost matrix for every market in your plan, or are you working from single-number estimates?
  2. Do you know the year one vs. recurring split for each market?
  3. Have you included local representative fees as annual recurring, not one-time?
  4. Have you separated US costs into a standalone business case with its own go/no-go decision?
  5. Have you stress-tested your budget with the upper end of each range, not the lower?
  6. Do you have translation memory in place for year-two maintenance savings?
  7. Is your sequencing driven by signed commercial commitments or by ambition?
  8. Have you included 20% contingency and is it visible to your CFO and board?

Frequently Asked Questions

Why is international market access more expensive than I expected? Because registration fees are the visible line and the four other layers are invisible until you hit them. The true cost is dominated by translation and local representative retainers, not authority fees.

Can I skip the authorised representative to save money? No. For most non-domestic manufacturers, a local representative is legally required. Skipping it means you cannot legally place on market.

How much should I budget for a realistic five-market year one if I am a class IIa European startup? A reasonable planning range, excluding the US, is EUR 50,000–100,000 for year one and EUR 20,000–40,000 recurring. Add the US as a separate line.

When does it make sense to enter the US market? When you have EU revenue, a US commercial hypothesis tested with real customers, and the capital to run a 510(k) program without starving your EU operations. Rarely in year one.

How do I reduce recurring cost without losing markets? Translation memory, multi-year representative contracts, combined audit cycles (MDSAP where applicable), and ruthless elimination of markets where you are not generating revenue.

Are the numbers in this post authoritative? They are realistic ranges based on typical startup programs. Actual costs vary with device class, complexity, notified body, translator rates, and negotiation. Always request current quotes from real providers before committing.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 11, 29, 31.
  2. Commission Implementing Regulation (EU) 2021/2078 — Eudamed rules.
  3. UK MHRA guidance on medical device registration (current version).
  4. US FDA device establishment registration and listing requirements (current annual user fee schedule).
  5. Swissmedic — Information sheet on CH-REP obligations (current version).
  6. Australian TGA — ARTG inclusion and annual charges (current fee schedule).